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Abstract. The conventional nonparametric tests in survival analysis, such as the log-
rank test, assess the null hypothesis that the hazards are equal at all times. However,
hazards are hard to interpret causally, and other null hypotheses are more relevant in
many scenarios with survival outcomes. To allow for a wider range of null hypotheses, we
present a generic approach to define test statistics. This approach utilizes the fact that
a wide range of common parameters in survival analysis can be expressed as solutions of
differential equations. Thereby we can test hypotheses based on survival parameters that
solve differential equations driven by cumulative hazards, and it is easy to implement
the tests on a computer. We present simulations, suggesting that our tests perform
well for several hypotheses in a range of scenarios. Finally, we use our tests to evaluate
the effect of adjuvant chemotherapies in patients with colon cancer, using data from a
randomised controlled trial.
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1. Introduction
The notion of hazards has been crucial for the development of modern survival analysis.
Hazards are perhaps the most natural parameters to use when fitting statistical models
to time-to-event data subject to censoring, and hazard functions were essential for the
development of popular methods like Cox regression and rank tests, which are routinely
used in practice.
In the field of causal inference, however, there is concern that many statisticians just do
advanced ’curve fitting’ without being careful about the interpretation of the parameters
that are reported [1, 2, 3]. This criticism can be directed to several areas in statistics. In
this spirit, we think that statisticians in general should pay particular attention to effect
measures with clear-cut causal interpretations.
In survival analysis, it has been acknowledged that interpreting hazards as effect mea-
sures is delicate, see e.g. [4] and [5]. This contrasts the more traditional opinion, in
which the proportional hazards model is motivated by the ’simple and easily understood
interpretation’ of hazard ratios [6, 4.3.a]. A key issue arises because the hazard, by def-
inition, is conditioned on previous survival. If we consider causal diagrams [3, 2], it is
clear that we condition on a ’collider’ that opens a non-causal pathway from the exposure
through any unobserved heterogeneity into the event of interest, see [4, 7, 8]. Since unob-
served heterogeneity is present in most practical scenarios, even in randomized trials, the
conditioning means that the hazards are fundamentally hard to interpret causally [4, 5].
Although we must be careful about assigning causal interpretations to hazards, we do
not claim that hazards are worthless. On the contrary, hazards are key elements in the
modelling of other parameters that are easier to interpret, serving as building blocks.
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This point of view is also found in [2, 17.1]: “..., the survival analyses in this book
privilege survival/risk over hazard. However, that does not mean that we should ignore
hazards. The estimation of hazards is often a useful intermediate step for the estimation
of survivals and risks.” Indeed, we have recently suggested a generic method to estimate
a range of effect measures in survival analysis, utilizing differential equations driven by
cumulative hazards [9].
Nevertheless, the conventional hypothesis tests in survival analysis are still based on
hazards. In particular the rank tests [10], including the log-rank test, are based on the
null hypothesis
H0: α
1
t = α
2
t for all t ∈ [0, T ],(1)
where αit is the hazard in group i. Formulating such hypotheses in a practical setting will
often imply that we assign causal interpretations to these hazard functions. In the sim-
plest survival setting this is not a problem, as there is a one-to-one relationship between
hazards and the survival curves, and a null hypothesis comparing two or more survival
curves is straightforward. In more advanced settings, e.g. scenarios with competing risks,
hypotheses like (1) are less transparent, leading to issues with interpretation [11]. For
example, in competing risks settings where competing events are treated as censoring
events, the null hypothesis in (1) is based on cause-specific hazards, which are often not
the target of inference [11].
We aimed to develop new hypothesis tests for time-to-event outcomes with two key
characteristics: First, the tests should be rooted in explicit null hypotheses that are easy
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to interpret. Second, the testing strategy should be generic, such that the scientist can
apply the test to their estimand of interest.
Survival parameters as solutions of differential equations
We will consider survival parameters that are functions solving differential equations
on the form
Xt = X0 +
∫ t
0
F (Xs)dAs,(2)
where A is a q dimensional vector of cumulative hazards, and F = (F1, · · · , Fq) : Rp −→
Rp×q is Lipschitz continuous with bounded and continuous first and second derivatives,
and satisfies a linear growth bound. The class of parameters also includes several quanti-
ties that are Lebesgue integrals, such that dAit = dt for some i. Here, X is a vector that
includes our estimand of interest, but X may also contain additional nuisance parameters
that are needed to formulate the estimand of interest.
Many parameters in survival analysis solve equations on the form (2). In particular,
the survival function can be expressed on the form (2) as St = 1−
∫ t
0
SsdAs, where A is the
cumulative hazard for death. Other examples include the cumulative incidence function,
the restricted mean survival function, and the prevalence function. We will present these
parameters in detail in Section 3. Nonparametric plugin estimators have been thoroughly
studied in [9]. The strategy assumes that A can be consistently estimated by
Aˆt =
∫ t
0
Gs−dNs,(3)
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where G is a q × l dimensional predictable process, and N is an l dimensional counting
process. Furthermore, we assume that Aˆ, the residuals W n =
√
n(Aˆ − A), and its
quadratic variation [W n], are so-called predictably uniformly tight. When the estimator
is a counting process integral, a relatively simple condition ensures predictable uniformly
tightness [9, Lemma 1]. Moreover, we suppose that
√
n(Aˆ−A) converges weakly (wrt the
Skorohod metric) to a mean zero Gaussian martingale with independent increments, see
[9, Lemma 1, Theorem 1 & 2] for details. Examples of estimators on the form (3) that
satisfy these criteria are the Nelson-Aalen estimator, or more generally Aalen’s additive
hazard estimator; if Aalen’s additive hazards model is a correct model for the hazard
A, then Aalen’s additive hazard model satisfy these criteria, in particular predictable
uniformly tightness.
Our suggested plugin estimator of X is obtained by replacing A with Aˆ, giving esti-
mators that solve the system
Xˆt = Xˆ0 +
∫ t
0
F (Xˆs−)dAˆs,(4)
where Xˆ0 is a consistent estimator of X0. When the estimand is the survival function,
this plugin estimator reduces to the Kaplan-Meier estimator. Ryalen et al [9] identified
the asymptotic distribution of
√
n(Xˆt−Xt) to be a mean zero Gaussian martingale with
covariance V solving a linear differential equation [9, eq. (17) ]. The covariance V can
also be consistently estimated by inserting the estimates Aˆ, giving rise to the system
Vˆt =Vˆ0 +
q∑
j=1
∫ t
0
Vˆs−∇Fj(Xˆs−)ᵀ +∇Fj(Xˆs−)Vˆs−dAˆjs
+ n
∫ t
0
F (Xˆs−)d[B]sF (Xˆs−)ᵀ,
(5)
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where {∇Fj}qj=1 are the Jacobian matrices of the columns of F = (F1, · · · , Fq) from (2),
and [B]t is a q × q matrix defined by
(
[B]t
)
i,j
=

0, if dAit = dt or dA
j
t = dt∑
s≤t
∆Aˆis∆Aˆ
j
s, otherwise.
The variance estimator (5), as well as the parameter estimator (4), can be expressed
as difference equations, and therefore they are easy to calculate generically in computer
programs. To be explicit, let τ1, τ2, . . . denote the ordered jump times of Aˆ. Then,
Xˆt = Xˆτk−1 + F (Xˆτk−1)∆Aˆτk , as long as τk ≤ t < τk+1. Similarly, the plugin variance
equation may be written as a difference equation,
Vˆt =Vˆτk−1 +
q∑
j=1
Vˆτk−1∇Fj(Xˆτk−1)ᵀ +∇Fj(Xˆτk−1)Vˆτk−1∆Aˆjτk
+ nF (Xˆτk−1)∆[B]τkF (Xˆτk−1)
ᵀ.
2. Hypothesis testing
The null hypothesis is not explicitly expressed in many research reports. On the con-
trary, the null hypothesis is often stated informally, e.g. vaguely indicating that a dif-
ference between two groups is assessed. Even if the null hypothesis is perfectly clear to
a statistician, this is a problem: the applied scientist, who frames the research question
based on subject-matter knowledge, may not have the formal understanding of the null
hypothesis.
In particular, we are not convinced that scientists faced with time-to-event outcomes
profoundly understand how null hypotheses based on hazard functions. Hence, using null
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hypotheses based on hazard functions, such as (1), may be elusive: in many scenarios,
the scientist’s primary interest is not to assess whether the hazard functions are equal
at all follow-up times. Indeed, the research question is often more focused, and the
scientist’s main concern can be contrasts of other survival parameters at a prespecified t
or in a prespecified time interval [12]. For example, we may aim to assess whether cancer
survival differs between two treatment regimens five years after diagnosis. Or we may
aim to assess whether a drug increases the average time to relapse in subjects with a
recurring disease. We will highlight that the rank tests are often not suitable for such
hypotheses.
Hence, instead of assessing hazards, let us study tests of (survival) parameters X1 and
X2 in groups 1 and 2 at a prespecified time t0. The null hypothesis is
HX0 : X
1,i
t0 = X
2,i
t0 for i = 1, · · · , p,(6)
where p is the dimension of X. We emphasize that the null hypothesis in (6) is different
from the null hypothesis in (1), as (6) is defined for any parameter Xt0 at a t0. We
will consider parameters X1 and X2 that solve (2); this is a broad class of important
parameters, including (but not limited to) the survival function, the cumulative incidence
function, the time dependent sensitivity and specificity functions, and the restricted mean
survival function [9].
2.1. Test statistics. We consider two groups 1 and 2 with population sizes n1, n2 and
let n = n1 + n2. We can estimate parameters X
1, X2 and covariance matrices V 1, V 2
using the plugin method described in Section 1. The contrast
√
n(Xˆ1t0 − Xˆ2t0) has an
asymptotic mean zero normal distribution under the null hypothesis. If the groups are
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independent, we may then use the statistic
(Xˆ1t0 − Xˆ2t0)Vˆ −1t0 (Xˆ1t0 − Xˆ2t0)ᵀ,(7)
to test for differences at t0, where Vˆt0 = Vˆ
1
t0
/n1 + Vˆ
2
t0
/n2, and where Vˆ
1
t0
and Vˆ 2 are calcu-
lated using the covariance matrix estimator (5). Then, the quantity (7) is asymptotically
χ2 distributed with p degrees of freedom under the null hypothesis, which is a corollary of
the results in [9], as we know from [9, Theorem 2] that
√
ni(Xˆ
i−X i) converges weakly to
mean zero Gaussian martingale whose covariance matrix V i can be consistently estimated
using (5). Therefore, under the null hypothesis (6), the root n difference of the estimates,
√
n(Xˆ1t0 − Xˆ2t0), will converge to a multivariate mean zero normal distribution with co-
variance matrix that can be estimated by n
(
Vˆ 1t0/n1 + Vˆ
2
t0
/n2
)
. Due to the continuous
mapping theorem, the statistic (7) has an asymptotic χ2 distribution.
Sometimes we may be interested in testing e.g. the r first components of X1 and X2,
under the null hypothesis X1,it0 = X
2,i
t0 for i = 1, · · · , r < p. It is straightforward to adjust
the hypothesis (6) and the test statistic, yielding the same asymptotic distribution with
r degrees of freedom.
3. Examples of test statistics
We derive test statistics for some common effect measures in survival and event history
analysis. By expressing the test statistics explicitly, our tests may be compared with the
tests based on conventional approaches.
3.1. Survival at t0. In clinical trials, the primary outcome may be survival at a pre-
specified t, e.g. cancer survival 5 years after diagnosis. Testing if survival at t is equal in
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two independent groups can be done in several ways [12], e.g. by estimating the variance
of Kaplan-Meier curves using Greenwood’s formula. However, we will highlight that our
generic tests also immediately deal with this scenario: it is straightforward to use the null
hypothesis in (6), where S1t and S
2
t are the survival functions in group 1 and 2 at time t.
Using the results in Section 2.1, we find that the plugin estimators of S1 and S2 are the
standard Kaplan-Meier estimators. The plugin variance in group i solves
Vˆ it = Vˆ
i
0 − 2
∫ t
0
Vˆ is−dAˆ
i
s + ni
∫ t
0
( Sˆis−
Y is
)2
dN is,(8)
for i ∈ {1, 2}, where Y is is the number at risk in group i just before time s. Assuming
that the groups are independent, the final variance estimator can be expressed as Vˆt =
Vˆ 1t /n1 + Vˆ
2
t /n2, and the statistic (7) becomes (Sˆ
1
t0
− Sˆ2t0)2/Vˆt0 , which is approximately χ2
distributed with 1 degree of freedom.
3.2. Restricted mean survival until t0. As an alternative to the hazard ratio, the
restricted mean survival has been advocated: it can be calculated without parametric
assumptions and it has a clear causal interpretation [13, 14, 15]. The plugin estimator of
the restricted mean survival difference between groups 1 and 2 is Rˆ1t−Rˆ2t =
∑
τk≤t
(
Sˆ1τk−1−
Sˆ2τk−1
)
∆τk, where ∆τk = τk − τk−1. The plugin estimator for the variance is
Vˆ R
i
t = Vˆ
Ri
0 + 2
∑
τk≤t
Vˆ R
i,Si
τk−1 ∆τk
Vˆ R
i,Si
t = Vˆ
Ri,Si
0 −
∫ t
0
Vˆ R
i,Si
s− dAˆ
i
s +
∑
τk≤t
Vˆ S
i
τk−1∆τk,
where Vˆ S
i
is the plugin variance for
√
niSˆ
i, given in (8). The statistic (7) can be used to
perform a test, with Vˆt0 = Vˆ
R1
t0
/n1 + Vˆ
R2
t0
/n2.
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3.3. Cumulative incidence at t0. Many time-to-event outcomes are subject to com-
peting risks. The Gray test is a competing risk analogue to the log-rank test: the null
hypothesis is defined by subdistribution hazards λt, such that λt =
d
dt
log[1 − Ct] where
Ct is the cumulative incidence of the event of interest, are equal at all t [16]. Analogous
to the log-rank test, the Gray test has low power if the subdistribution hazard curves
are crossing [17]. However, we are often interested in evaluating the cumulative incidence
at a time t0, without making assumptions about the subdistribution hazards, which are
even harder to interpret causally than standard hazard functions. By expression the
cumulative incidence on the form (2), we use our transformation procedure to obtain a
test statistic for the cumulative incidence at t0. The plugin estimator for the cumulative
incidence difference is
Cˆ1t − Cˆ2t =
∫ t
0
Sˆ1s−dAˆ
1,j
s −
∫ t
0
Sˆ2s−dAˆ
2,j
s ,
where Ai,j is the cumulative cause-specific hazard for the event j of interest, and Sˆi is
the Kaplan-Meier estimate within group i. The groupwise plugin variances solve
Vˆ it = Vˆ
i
0 + 2
∫ t
0
Vˆ is−dAˆ
i,j
s + ni
∫ t
0
( Sˆis−
Y is
)2
dN i,js ,
where N i,j counts the event of interest.
3.4. Frequency of recurrent events. Many time-to-event outcomes are recurrent events.
For example, time to hospitalization is a common outcome in medical studies, such as
trials on cardiovascular disease. Often recurrent events are analysed with conventional
methods, in particular the Cox model, restricting the analysis to only include the first
event in each subject. A better solution may be to study the mean frequency function,
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i.e. the marginal expected number of events until time t, acknowledging that the subject
can not experience events after death [18]. We let Ai,E and Ai,D be the cumulative haz-
ards for the recurrent event and death in group i, respectively, and let Ki and Si be the
mean frequency function and survival, respectively. Then, the plugin estimator of the
difference is
Kˆ1t − Kˆ2t =
∫ t
0
Sˆ1s−dAˆ
1,E
s −
∫ t
0
Sˆ2s−dAˆ
2,E
s .
The plugin variances solve
Vˆ K
i
t = Vˆ
Ki
0 +
∫ t
0
Vˆ K
i,Si
s− d(Aˆ
i,E
s − Aˆi,Ds ) + ni
∫ t
0
( Sˆis−
Y is
)2
dN i,Es ,
Vˆ K
i,Si
t = Vˆ
Ki,Si
0 −
∫ t
0
Vˆ K
i,Si
s− dAˆ
i,D
s +
∫ t
0
Vˆ S
i
s−dAˆ
i,E
s ,
where N i,E counts the recurrent event, and where Vˆ S
i
is the survival plugin variance in
group i, as displayed in (8).
3.5. Prevalence in an illness-death model. The prevalence denotes the number of
individuals with a condition at a specific time, which is e.g. useful for evaluating the
burden of a disease. We consider a simple Markovian illness-death model with three
states: healthy:0, ill:1, dead:2. The population is assumed to be healthy initially, but
individuals may get ill or die as time goes on. We aim to study the prevalence P i,1t of the
illness in group i as a function of time. Here, we assume that the illness is irreversible, but
we could extend this to a scenario in which recovery from the illness is possible, similar
to Bluhmki [19]. Let Ai,kj be the cumulative hazard for transitioning from state k to j
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in group i. Then, P i,1 solves the system
P i,0t
P i,1t
 =
1
0
+ ∫ t
0
−P i,0s −P i,0s 0
P i,0s 0 −P i,1s
 d

Ai,01s
Ai,02s
Ai,12s
 .
The plugin estimator for the difference P 1,1 − P 2,1 is
Pˆ 1,1t − Pˆ 2,1t =
∫ t
0
Pˆ 1,0s− dAˆ
1,01
s −
∫ t
0
Pˆ 2,0s− dAˆ
2,01
s −
∫ t
0
Pˆ 1,1s− dAˆ
1,01
s +
∫ t
0
Pˆ 2,1s− dAˆ
2,01
s .
The variance estimator for group i reads
Vˆ P
i,1
t = Vˆ
P i,1
0 + 2
∫ t
0
Vˆ P
i,0,P i,1
s− dAˆ
i,01
s − 2
∫ t
0
Vˆ P
i,1
s− dAˆ
i,12
s
+ ni
(∫ t
0
( Pˆ i,0s−
Y i,0s
)2
dN i,01s +
∫ t
0
( Pˆ i,1s−
Y i,1s
)2
dN i,12s
)
Vˆ P
i,0,P i,1
t = Vˆ
P i,0,P i,1
0 +
∫ t
0
(
Vˆ P
i,0
s− − Vˆ P
i,0,P i,1
s−
)
dAˆi,01s −
∫ t
0
Vˆ P
i,0,P i,1
s− dAˆ
i,02
s
−
∫ t
0
Vˆ P
i,0,P i,1
s− dAˆ
i,12
s − ni
∫ t
0
( Pˆ i,0s−
Y i,0s
)2
dN i,01s
Vˆ P
i,0
t = Vˆ
P i,0
0 − 2
∫ t
0
Vˆ P
i,0
s− dAˆ
i,01
s − 2
∫ t
0
Vˆ P
i,0
s− dAˆ
i,02
s
+ ni
∫ t
0
( Pˆ i,0s−
Y i,0s
)2
d
(
N i,01s +N
i,02
s
)
.
Here, Y i,0, Y i,1 are the number of individuals at risk in states 0 and 1, while N i,kj counts
the transitions from state k to j in group i. By calculating Vˆ P
i,1
t for i ∈ {1, 2}, we
can find the statistic (7). Here, the prevalence is measured as the proportion of affected
individuals relative to the population at t = 0. We could use a similar approach to
consider the proportion of affected individuals relative to the surviving population at t,
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or we could record the cumulative prevalence until t to evaluate the cumulative disease
burden.
4. Performance
In this section, we present power functions under several scenarios for the test statistics
that were presented in Section 3. The scenarios were simulated by defining different
relations between the hazard functions in the two exposure groups: (i) constant hazards
in both groups, (ii) hazards that were linearly crossing, and (iii) hazards that were equal
initially before diverging after a time t.
For each hazard relation (i)-(iii), we defined several κ’s such that the true parameter
difference was equal to κ at the prespecified time point t0, i.e. X
1
t0
−X2t0 = κ. For each
combination of target parameter, difference κ, and hazard scenario, we replicated the
simulations m times to obtain m realizations of (7), and we artificially censored 10%
of the subjects in each simulation. In the Supplementary material, we show additional
simulations with different sample sizes (50, 100 and 500) and fractions of censoring (10%-
40%). We have provided an overview of the simulations in figure 2, in which parameters
of interest (solid lines) and hazard functions (dashed lines) are displayed in scenarios with
fixed κ = −0.05 at t0 = 1.5, i.e. X11.5 −X21.5 = −0.05.
In each scenario, we rejected HX0 at the 5% confidence level. Thus, we obtained m
Bernoulli trials in which the success probability is the power function evaluated at κ.
The estimated power functions, i.e. the estimates of the Bernoulli probabilities, are dis-
played in figure 3 (solid lines). The power functions are not affected by the structure of
the underlying hazards, as desired: our tests are only defined at t0, and the particular
parameterization of the hazard has minor impact on the power function.
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The dashed lines in figure 3 show power functions of alternative nonparametric test
statistics that are already found in the literature, tailor-made for the scenario of interest.
In particular, for the survival at t, we obtained a test statistic using Greenwood’s variance
formula (and a cloglog transformation in the Supplementary Material) [12]. For the
restricted mean survival at t, we used the statistic suggested in [15]. For the cumulative
incidence at t, we used the statistic suggested in [20]. For the mean frequency function we
used the estimators derived in [18], and in the prevalence example we used the variance
formula in [21, p. 295], as implemented in the etm package in R. Our generic strategy
gave similar power compared to the conventional methods for each particular scenario.
4.1. Comparisons with the log-rank test. We have argued that our tests are funda-
mentally different from the rank tests, as the null hypotheses are different. Nevertheless,
since rank tests are widely used in practice, also when the primary interest seems to be
other hypothesis than in (1), we aimed to compare the power of our test statistics with
the log-rank test under different scenarios. In table 3, we compared the power of our
test statistic and the rank test, using the scenarios in figure 2. In the first column, the
proportional hazards assumption is satisfied (constant), and therefore the power of the
log-rank test is expected to be optimal (assuming no competing risks). Our tests of the
survival function and the restricted mean survival function show only slightly reduced
power compared to the log rank test. For the cumulative incidence function at a time
t0, our test is less powerful than the Gray test and the log-rank test of the cause specific
hazards. However, the cause specific hazard test have type one error rate is not nominal,
which we will return to in the end of this section.
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The second column displays power of tests under scenarios with crossing hazards. For
the survival function, it may seem surprising that the log-rank test got higher power than
our test, despite the crossing hazards. However, in this particular scenario the hazards
are crossing close to the end of the study (dashed lines in Figure 2), and therefore the
crossing has little impact on the power of the log-rank test. In contrast, the power of
the log-rank test is considerably reduced in the scenarios where we study the restricted
mean survival function and the cumulative incidence functions, in which the hazards are
crossing at earlier points in time.
The third column shows the power under hazards that are deviating. For the survival
function, our test provides higher power. Intuitively, the log-rank test has less power in
this scenario because the hazards are equal or close to equal during a substantial fraction
of the follow-up time. For the restricted mean survival, however, the log-rank has more
power. This is not surprising [15], and it is due to the particular simulation scenario:
Late events have relatively little impact on the restricted mean survival time, and in
this scenario a major difference between the hazards was required to obtain κ. Since the
log-rank test is sensitive to major differences in the hazards, it has more power in this
scenario. For the cumulative incidence, in contrast, the power of the log-rank test is lower
than the power of our test.
The results in table 3 illustrate that power depends strongly on the hazard scenario
for the log-rank test, but this dependence is not found for our tests.
To highlight the basic difference between the log-rank test and our tests, we have
studied scenarios where HX0 in (6) is true (figure 4). That is, at t0 = 1.5 the difference
X1t0 − X2t0 = 0, but for earlier times the equality does not hold. In these scenarios, the
log-rank test got high rates of type 1 errors. Heuristically, this is expected because the
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hazards are different at most (if not all) times t ∈ [0, t0]. Nevertheless, figure 4 confirms
that the log-rank test does not have the correct type 1 error rate under null hypotheses
as in (6), and should not be used for such tests, even if the power sometimes is adequate
(as in table 3).
5. Example: Adjuvant chemotherapy in patients with colon cancer
To illustrate how our tests can be applied in practice, we assessed the effectiveness of
two adjuvant chemotherapy regimes in patients with stage III colon cancer, using data
that are available to anyone [22, 23]. The analysis is performed as a worked example in the
supplementary data using the R package transform.hazards. After undergoing surgery,
929 patients were randomly assigned to observation only, levamisole (Lev) or levamisole
plus fluorouracil (Lev+5FU) [22]. We restricted our analysis to the 614 subjects who got
Lev or Lev+5FU. All-cause mortality and the cumulative incidence of cancer recurrence
was lower in subjects receiving (Lev+5FU), as displayed in Figure 1.
We formally assessed the comparative effectivness of Lev and Lev+5FU after 1 and 5
years of follow-up, using the parameters from section 3. After 1 year, both the overall
survival and the restricted mean survival were similar in the two treatment arms (Table
1). However, the cumulative incidence of recurrence was reduced in the Lev+5FU group,
and the number of subjects alive with recurrent disease were lower in the Lev+5FU group.
Also, the mean time spent alive and without recurrence was longer in the Lev+5FU group
(Table 1, Restricted mean recurrence free survival). These results suggest that Lev+5FU
has a beneficial effect on disease recurrence after 1 year of follow-up compared to Lev.
After 5 years of follow-up, overall survival and restricted mean survival was improved in
the Lev+5FU group (Table 2). Furthermore, the cumulative incidence of recurrence was
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reduced, and the prevalence of patients with recurrence was lower in the Lev+5FU group.
These results suggest that Lev+5FU improves overall mortality and reduces recurrence
after 1 year compared to Lev.
In conclusion, our analysis indicates that treatment with Lev+5FU improves several
clinically relevant outcomes in patients with stage III colon cancer. We also emphasise
that a conventional analysis using a proportional hazards model would not be ideal here,
as the plots in Figure 1 indicate violations of the proportional hazards assumptions.
6. Covariate adjustments
Our approach allows us to conduct tests conditional on baseline covariates, using the
additive hazard model; by letting the cumulative hazard integrand in (2) be conditional
on specific covariates, we can test for conditional differences between groups, assuming
that the underlying hazards are additive.
In more detail, we can test for differences between group 1 and 2 under the covariate
level Z = z0 by evaluating the cumulative hazards in each group at that level, yielding
A1,z0 and A2,z0 . Estimates Aˆ1,z0 and Aˆ2,z0 can be found using standard software. This
allows us to estimate parameters with covariances using (4) and (5), and test the null
hypothesis of no group difference within covariate level z0 using the test statistic (7),
again assuming that the groups are independent.
7. Discussion
By expressing survival parameters as solutions of differential equations, we provide
generic hypothesis tests for survival analysis. In contrast to the conventional approaches
that are based on hazard functions [24, Section 3.3], our null hypotheses are defined with
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respect to explicit parameters, defined at a time t0. Our strategy also allows for covariate
adjustment under additive hazard models.
We have presented some examples of parameters, and our simulations suggest that the
test statistics are well-behaved in a range of scenarios. Indeed, for common parameters
such as the survival function, the restricted mean survival function and the cumulative in-
cidence function, our tests obtain similar power to conventional tests that are tailor made
for a particular parameter. Importantly, our examples do not comprise a comprehensive
set of relevant survival parameters, and several other effect measures for event histories
may be described on the differential equation form (2), allowing for immediate imple-
mentation of hypothesis tests, for example using the R package transforming.hazards
[9, 8]. The fact that our derivations are generic and easy to implement for customized
parameters, is a major advantage.
Our tests differ from the rank tests, as the rank tests are based on assessing the
equality of the hazards during the entire follow-up. However, our strategy is intended to
be different: We aimed to provide tests that apply to scenarios where the null hypothesis
of the rank tests is not the primary interests.
Restricting the primary parameter to a single time t0 is sometimes considered to be
a caveat. In particular, we ignore the time-dependent profile of the parameters before
and after t0. For some parameters, such as the survival function or the cumulative
incidence function, this may be a valid objection in principle. However, even if our
primary parameter is assessed at t0, this parameter may account for the whole history
of events until t0. One example is the restricted mean survival, which considers the
history of events until t0. Indeed, the restricted mean survival has been suggested as an
alternative effect measure to the hazard ratio, because it is easier to interpret causally,
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and it does not rely on the proportional hazards assumption [14]. An empirical analysis
of RCTs showed that tests of the restricted mean survival function yield results that are
concordant with log-rank tests, under the conventional null hypothesis in (1) [14], and
similar results were found in an extensive simulation study [15].
Furthermore, the time-dependent profile before t0 is not our primary interest in many
scenarios. In medicine, for example, we may be interested in comparing different treat-
ment regimes, such as radiation and surgery for a particular cancer. Then, time to
treatment failure is expected to differ in the shorter term due to the fundamental dif-
ference between the treatment regimes, but the study objective is to assess longer-term
treatment differences [25]. Similarly, in studies of cancer screening, it is expected that
more cancers are detected early in the screening arm, but the scientist’s primary aim is
often to assess long-term differences between screened and non-screened. In such scenar-
ios, testing at a prespecified t0 are more desirable than the null-hypothesis of the rank
tests.
Nevertheless, we must assure that cherry picking of t0 is avoided. In practice, there
will often be a natural value of t0. For example, t0 (or multiple t1, t2, · · · , tk) can be
prespecified in the protocol of clinical trials. In cancer studies, a common outcome is e.g.
five year survival. Alternatively, t0 can be selected based on when a certain proportion is
lost to censoring. Furthermore, using confidence bands, rather than pointwise confidence
intervals and p-values, is an appealing alternative when considering multiple points in
time. There exist methods to estimate confidence bands based on wild bootstrap for
competing risks settings [26], which were recently extended to reversible multistate models
allowing for illness-death scenarios with recovery [19]. We aim to develop confidence bands
for our estimators in future research.
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Finally, we are often interested in assessing causal parameters using observational data,
under explicit assumptions that ensure no confounding and no selection bias. Such pa-
rameters may be estimated after weighting the original data [8, 27]. Indeed, weighted
point estimators are consistent when our approach is used [8], but we would also like to
identify the asymptotic root n residual distribution, allowing us to estimate covariance
matrices that are appropriate for the weighted parameters. We consider this to be an
important direction for future work. Currently, such covariance matrices can only be
obtained from bootstrap samples.
8. Software
We have implemented a generic procedure for estimating parameters and covariance
matrices in an R package, available for anyone to use on github.com/palryalen/transform.hazards.
It allows for hypothesis testing at prespecified time points using (6). Worked examples
can be found the package vignette, or in the supplementary material here.
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Table 1. Estimates, 95% confidence intervals and p-values after 1 year
Lev Lev+5FU p-value
Survival 0.91 (0.87,0.94) 0.92 (0.89,0.95) 0.62
Restricted mean survival 0.96 (0.95,0.98) 0.97 (0.95,0.98) 0.86
Cumulative incidence 0.27 (0.22,0.32) 0.15 (0.11,0.19) 0
Prevalence 0.19 (0.14,0.23) 0.09 (0.05,0.12) 0
Restricted mean recurrence free survival 0.85 (0.82,0.88) 0.90 (0.87,0.92) 0.01
Table 2. Estimates, 95% confidence intervals and p-values after 5 years
Lev Lev+5FU p-value
Survival 0.54 (0.48,0.59) 0.63 (0.58,0.69) 0.01
Restricted mean survival 3.62 (3.44,3.81) 3.97 (3.79,4.15) 0.01
Cumulative incidence 0.47 (0.42,0.51) 0.34 (0.29,0.39) 0
Prevalence 0.07 (0.05,0.10) 0.03 (0.02,0.05) 0.02
Restricted mean recurrence free survival 2.29 (2.07,2.51) 2.95 (2.73,3.18) 0
Table 3. Power comparisons of our tests and rank tests (our/rank) for the
scenarios displayed in figure 2, comparing two groups of 1500 individuals
(based on 400 replications). In the lower row, we also display the power of
Gray’s test for competing risks (our/rank/Gray). The power of the rank
tests is sensitive to the shape of the underlying hazards, while the power
of our tests vary little across the scenarios. In particular, the power of the
rank tests is very sensitive to the rate of change of the hazards when they
are crossing or deviating; see also the third column of figure 2.
Parameter \ Hazard Constant Crossing Deviating
Survival 0.81/0.88 0.79/0.96 0.83/0.70
Restricted mean survival 0.77/0.87 0.78/0.21 0.8/1
Cumulative incidence 0.85/0.94/0.88 0.86/0.80/0.70 0.86/0.83/0.76
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Figure 1. Survival curves (left) and the cumulative incidence of recur-
rence (right) along with 95% pointwise confidence intervals (shaded) from
the colon cancer trial are displayed.
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Figure 2. Simulation scenarios in which the true parameter difference was
fixed to κ = −0.05 at t0 = 1.5, i.e. X11.5 − X21.5 = −0.05. The upper row
shows survival, the middle row shows restricted mean survival, and lower
row shows cumulative incidences. The hazards are displayed as dotted lines;
constant in the left column, linearly crossing in the middle column, and
deviating in the right column. The X1 parameters/hazards are black, and
the X2 parameters/hazards are green. See Table 3 for a power comparison
of our tests and the rank tests for the scenarios that are displayed. The
cumulative incidence panels: The cause specific hazards for the competing
event are held constant equal to 0.4 at all times. We optimize the cause
specific hazards for the event of interest so that X11.5−X21.5 = −0.05 under
the restrictions that they are constant (left), linearly crossing (middle), and
equal before deviating (right).
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Figure 3. Estimated power functions for constant (black), crossing
(green), and deviating (blue) hazards, based on 250 subjects with a repli-
cation number of 400. The dashed lines show test statistics derived from
existing methods in the literature, that are tailor-made for the particular
scenario. The confidence level is shown by the gray lines.
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Figure 4. In the upper row, we display hazards functions in scenarios
in which the hazard in group 1 is fixed (black line), and the hazards in
group 2 varies (grey lines). The hazards are optimized such that the null
hypothesis is true, i.e. X1t0 = X
2
t0
for each combination of black/gray
hazards at t0 = 1.5. In the lower rows we show the estimated rejection
rate as a function of the ratio of the hazard slopes (slope of gray/slope of
black). This is done for sample sizes sample sizes 500 (row 2), 1000 (row
3), and 5000 (row 4) with a replication number of 500. The green curve
shows the rejection rate of the log-rank test, while the black curve shows the
rejection rate of our tests, which appear to be well calibrated along the 5%
significance level. If the sample size is large, the rank tests can falsely reject
the null hypothesis even when the hazards are crossing. The cumulative
incidence panels: We only show the cause-specific hazards for the event of
interest (which we compare using the rank test). The cause-specific hazard
for the competing event is equal to 0.4 in both groups.
